GURUFOCUS.COM » STOCK LIST » USA » NAS » Intercept Pharmaceuticals Inc (NAS:ICPT) » Definitions » Float Percentage Of Total Shares Outstanding
Switch to:

Intercept Pharmaceuticals (NAS:ICPT) Float Percentage Of Total Shares Outstanding

: 96.22% (As of Today)
View and export this data going back to 2012. Start your Free Trial

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Intercept Pharmaceuticals's float shares is 40.11 Mil. Intercept Pharmaceuticals's total shares outstanding is 41.69 Mil. Intercept Pharmaceuticals's float percentage of total shares outstanding is 96.22%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Intercept Pharmaceuticals's Insider Ownership is 4.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Intercept Pharmaceuticals's Institutional Ownership is 43.05%.


Intercept Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Intercept Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=40.11/41.69
=96.22%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intercept Pharmaceuticals (NAS:ICPT) Business Description

Intercept Pharmaceuticals logo
Industry
Traded in Other Exchanges
Address
10 Hudson Yards, 37th Floor, New York, NY, USA, 10001
Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
Executives
Andrew Saik officer: EVP & Chief Financial Officer 640 LEE ROAD, CHESTERBROOK PA 19087
M Michelle Berrey officer: President, R&D and CMO 303A COLLEGE ROAD EAST, PRINCETON NJ 08450
Dagmar Rosa-bjorkeson director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Rocco Venezia officer: Chief Accounting Officer C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FLOOR, NEW YORK NY 10001
Lisa Defrancesco officer: SVP, IR & Corp. Affairs C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, FLOOR 37, NEW YORK NY 10001
Linda M Richardson officer: EVP & Chief Commercial Officer 2505 MERIDIAN PKWY, SUITE 340, C/O CHIMERIX, INC., DURHAM NC 27713
Jared Freedberg officer: General Counsel and Secretary 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Bryan Ball officer: Chief Quality Officer 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Paolo Fundaro director, 10 percent owner C/O GENEXTRA S.P.A.,, VIA G. DE GRASSI, 11, MILAN L6 20123
Keith Michael Gottesdiener director 900 FIFTH AVENUE, #8C, NEW YORK NY 10021
Luca Benatti director C/O INTERCEPT PHARMACEUTICALS, INC., 450 WEST 15TH STREET, SUITE 505, NEW YORK NY 10011
Daniel G Welch director 4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707
Daniel Bradbury director BIOBRIT, LLC, 2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037
Nancy Miller-rich director C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FL, NEW YORK NY 10001
Gino Santini director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451

Intercept Pharmaceuticals (NAS:ICPT) Headlines

Other Sources